228 related articles for article (PubMed ID: 28851812)
1. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.
Yochum ZA; Cades J; Mazzacurati L; Neumann NM; Khetarpal SK; Chatterjee S; Wang H; Attar MA; Huang EH; Chatley SN; Nugent K; Somasundaram A; Engh JA; Ewald AJ; Cho YJ; Rudin CM; Tran PT; Burns TF
Mol Cancer Res; 2017 Dec; 15(12):1764-1776. PubMed ID: 28851812
[TBL] [Abstract][Full Text] [Related]
2. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.
Burns TF; Dobromilskaya I; Murphy SC; Gajula RP; Thiyagarajan S; Chatley SN; Aziz K; Cho YJ; Tran PT; Rudin CM
Mol Cancer Res; 2013 Apr; 11(4):329-38. PubMed ID: 23364532
[TBL] [Abstract][Full Text] [Related]
4. TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.
Kumar V; Yochum ZA; Devadassan P; Huang EH; Miller E; Baruwal R; Rumde PH; GaitherDavis AL; Stabile LP; Burns TF
Oncogene; 2024 May; 43(19):1431-1444. PubMed ID: 38485737
[TBL] [Abstract][Full Text] [Related]
5. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
[TBL] [Abstract][Full Text] [Related]
6. ETS1 regulates Twist1 transcription in a Kras
Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
[TBL] [Abstract][Full Text] [Related]
7. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.
Tran PT; Shroff EH; Burns TF; Thiyagarajan S; Das ST; Zabuawala T; Chen J; Cho YJ; Luong R; Tamayo P; Salih T; Aziz K; Adam SJ; Vicent S; Nielsen CH; Withofs N; Sweet-Cordero A; Gambhir SS; Rudin CM; Felsher DW
PLoS Genet; 2012; 8(5):e1002650. PubMed ID: 22654667
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
9. Synaptotagmin 7 in twist-related protein 1-mediated epithelial - Mesenchymal transition of non-small cell lung cancer.
Liu X; Li C; Yang Y; Liu X; Li R; Zhang M; Yin Y; Qu Y
EBioMedicine; 2019 Aug; 46():42-53. PubMed ID: 31395502
[TBL] [Abstract][Full Text] [Related]
10. Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1.
Nafie E; Lolarga J; Lam B; Guo J; Abdollahzadeh E; Rodriguez S; Glackin C; Liu J
PLoS One; 2021; 16(2):e0247652. PubMed ID: 33626096
[TBL] [Abstract][Full Text] [Related]
11. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
12. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Non-Small Cell Lung Cancer Growth and Metastasis by a Novel Small Molecular Activator of RECK.
Shen J; Wang B; Zhang T; Zhu N; Wang Z; Jin J; He Y; Hu M
Cell Physiol Biochem; 2018; 45(5):1807-1817. PubMed ID: 29510387
[TBL] [Abstract][Full Text] [Related]
14. TPPP3 Promotes Cell Proliferation, Invasion and Tumor Metastasis via STAT3/ Twist1 Pathway in Non-Small-Cell Lung Carcinoma.
Li Y; Bai M; Xu Y; Zhao W; Liu N; Yu J
Cell Physiol Biochem; 2018; 50(5):2004-2016. PubMed ID: 30404076
[TBL] [Abstract][Full Text] [Related]
15. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
16. Positive feedback loop of lncRNA LINC01296/miR-598/Twist1 promotes non-small cell lung cancer tumorigenesis.
Xu L; Wei B; Hui H; Sun Y; Liu Y; Yu X; Dai J
J Cell Physiol; 2019 Apr; 234(4):4563-4571. PubMed ID: 30240003
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
18. Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC).
Gorgisen G; Ozes D; Pehlivanoglu S; Erdogan A; Dertsiz L; Ozbilim G; Ozbudak IH; Savas B; Ozes ON
Exp Lung Res; 2013 Nov; 39(9):387-98. PubMed ID: 24117170
[TBL] [Abstract][Full Text] [Related]
19. TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma.
Pallier K; Cessot A; Côté JF; Just PA; Cazes A; Fabre E; Danel C; Riquet M; Devouassoux-Shisheboran M; Ansieau S; Puisieux A; Laurent-Puig P; Blons H
PLoS One; 2012; 7(1):e29954. PubMed ID: 22272264
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]